Engraftment and survival after unrelated-donor bone marrow transplantation: A report from the national marrow donor program

Stella M. Davies, Craig Kollman, Claudio Anasetti, Joseph H. Antin, James Gajewski, James T. Casper, Auayporn Nademanee, Harriet Moreen, Roberta King, Dennis Confer, Nancy A. Keman

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

We analyzed engraftment of unrelated-donor (URD) bone marrow in 5246 patients who received transplants facilitated by the National Marrow Donor Program between August 1991 and June 1999. Among patients surviving at least 28 days, 4% had primary graft failure (failure to achieve an absolute neutrophil count > 5 x 108/L before death or second stem-cell infusion). Multivariate logistic regression analysis showed that engraftment was associated with marrow matched at HLA-A, HLA-B, and DRB1; higher cell dose; younger recipient; male recipient; and recipient from a non -African American ethnic group. More rapid myeloid engraftment was associated with marrow serologically matched at H L A-A and HLA-B, DRB1 match, higher cell dose (in non-T-cell-depleted cases), younger recipient, recipient seronegativity for cytomegalovirus (CMV), male donor, no methotrexate for graft-versus-host disease prophylaxis, and transplantation done in more recent years. A platelet count higher than 50 x 109/L was achieved by 47% of patients by day 100. Conditional on survival to day 100, survival at 3 years was 61% in those with platelet engraftment at day 30, 58% in those with engraftment between day 30 and day 100, and 33% in those without engraftment at day 100 (P <.0001). Factors favoring platelet engraftment were higher cell dose, DRB1 allele match, recipient seronegativity for CMV, HLA-A and H L A-B serologically matched donor, and male donor. Secondary graft failure occurred in 10% of patients achieving initial engraftment, and 18% of those patients are alive. These data demonstrate that quality of engraftment is an important predictor of survival after URD bone marrow transplantation.

Original languageEnglish (US)
Pages (from-to)4096-4102
Number of pages7
JournalBlood
Volume96
Issue number13
StatePublished - 2000
Externally publishedYes

Fingerprint

Unrelated Donors
Platelets
Bone Marrow Transplantation
Grafts
Bone
HLA-A Antigens
HLA-B Antigens
Bone Marrow
Tissue Donors
Survival
HLA-DRB1 Chains
Transplantation (surgical)
Transplants
Cytomegalovirus
Stem cells
Methotrexate
Regression analysis
Blood Platelets
Logistics
Cells

ASJC Scopus subject areas

  • Hematology

Cite this

Davies, S. M., Kollman, C., Anasetti, C., Antin, J. H., Gajewski, J., Casper, J. T., ... Keman, N. A. (2000). Engraftment and survival after unrelated-donor bone marrow transplantation: A report from the national marrow donor program. Blood, 96(13), 4096-4102.

Engraftment and survival after unrelated-donor bone marrow transplantation : A report from the national marrow donor program. / Davies, Stella M.; Kollman, Craig; Anasetti, Claudio; Antin, Joseph H.; Gajewski, James; Casper, James T.; Nademanee, Auayporn; Moreen, Harriet; King, Roberta; Confer, Dennis; Keman, Nancy A.

In: Blood, Vol. 96, No. 13, 2000, p. 4096-4102.

Research output: Contribution to journalArticle

Davies, SM, Kollman, C, Anasetti, C, Antin, JH, Gajewski, J, Casper, JT, Nademanee, A, Moreen, H, King, R, Confer, D & Keman, NA 2000, 'Engraftment and survival after unrelated-donor bone marrow transplantation: A report from the national marrow donor program', Blood, vol. 96, no. 13, pp. 4096-4102.
Davies SM, Kollman C, Anasetti C, Antin JH, Gajewski J, Casper JT et al. Engraftment and survival after unrelated-donor bone marrow transplantation: A report from the national marrow donor program. Blood. 2000;96(13):4096-4102.
Davies, Stella M. ; Kollman, Craig ; Anasetti, Claudio ; Antin, Joseph H. ; Gajewski, James ; Casper, James T. ; Nademanee, Auayporn ; Moreen, Harriet ; King, Roberta ; Confer, Dennis ; Keman, Nancy A. / Engraftment and survival after unrelated-donor bone marrow transplantation : A report from the national marrow donor program. In: Blood. 2000 ; Vol. 96, No. 13. pp. 4096-4102.
@article{fb7890ead648448ab3df05de00cc3a16,
title = "Engraftment and survival after unrelated-donor bone marrow transplantation: A report from the national marrow donor program",
abstract = "We analyzed engraftment of unrelated-donor (URD) bone marrow in 5246 patients who received transplants facilitated by the National Marrow Donor Program between August 1991 and June 1999. Among patients surviving at least 28 days, 4{\%} had primary graft failure (failure to achieve an absolute neutrophil count > 5 x 108/L before death or second stem-cell infusion). Multivariate logistic regression analysis showed that engraftment was associated with marrow matched at HLA-A, HLA-B, and DRB1; higher cell dose; younger recipient; male recipient; and recipient from a non -African American ethnic group. More rapid myeloid engraftment was associated with marrow serologically matched at H L A-A and HLA-B, DRB1 match, higher cell dose (in non-T-cell-depleted cases), younger recipient, recipient seronegativity for cytomegalovirus (CMV), male donor, no methotrexate for graft-versus-host disease prophylaxis, and transplantation done in more recent years. A platelet count higher than 50 x 109/L was achieved by 47{\%} of patients by day 100. Conditional on survival to day 100, survival at 3 years was 61{\%} in those with platelet engraftment at day 30, 58{\%} in those with engraftment between day 30 and day 100, and 33{\%} in those without engraftment at day 100 (P <.0001). Factors favoring platelet engraftment were higher cell dose, DRB1 allele match, recipient seronegativity for CMV, HLA-A and H L A-B serologically matched donor, and male donor. Secondary graft failure occurred in 10{\%} of patients achieving initial engraftment, and 18{\%} of those patients are alive. These data demonstrate that quality of engraftment is an important predictor of survival after URD bone marrow transplantation.",
author = "Davies, {Stella M.} and Craig Kollman and Claudio Anasetti and Antin, {Joseph H.} and James Gajewski and Casper, {James T.} and Auayporn Nademanee and Harriet Moreen and Roberta King and Dennis Confer and Keman, {Nancy A.}",
year = "2000",
language = "English (US)",
volume = "96",
pages = "4096--4102",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Engraftment and survival after unrelated-donor bone marrow transplantation

T2 - A report from the national marrow donor program

AU - Davies, Stella M.

AU - Kollman, Craig

AU - Anasetti, Claudio

AU - Antin, Joseph H.

AU - Gajewski, James

AU - Casper, James T.

AU - Nademanee, Auayporn

AU - Moreen, Harriet

AU - King, Roberta

AU - Confer, Dennis

AU - Keman, Nancy A.

PY - 2000

Y1 - 2000

N2 - We analyzed engraftment of unrelated-donor (URD) bone marrow in 5246 patients who received transplants facilitated by the National Marrow Donor Program between August 1991 and June 1999. Among patients surviving at least 28 days, 4% had primary graft failure (failure to achieve an absolute neutrophil count > 5 x 108/L before death or second stem-cell infusion). Multivariate logistic regression analysis showed that engraftment was associated with marrow matched at HLA-A, HLA-B, and DRB1; higher cell dose; younger recipient; male recipient; and recipient from a non -African American ethnic group. More rapid myeloid engraftment was associated with marrow serologically matched at H L A-A and HLA-B, DRB1 match, higher cell dose (in non-T-cell-depleted cases), younger recipient, recipient seronegativity for cytomegalovirus (CMV), male donor, no methotrexate for graft-versus-host disease prophylaxis, and transplantation done in more recent years. A platelet count higher than 50 x 109/L was achieved by 47% of patients by day 100. Conditional on survival to day 100, survival at 3 years was 61% in those with platelet engraftment at day 30, 58% in those with engraftment between day 30 and day 100, and 33% in those without engraftment at day 100 (P <.0001). Factors favoring platelet engraftment were higher cell dose, DRB1 allele match, recipient seronegativity for CMV, HLA-A and H L A-B serologically matched donor, and male donor. Secondary graft failure occurred in 10% of patients achieving initial engraftment, and 18% of those patients are alive. These data demonstrate that quality of engraftment is an important predictor of survival after URD bone marrow transplantation.

AB - We analyzed engraftment of unrelated-donor (URD) bone marrow in 5246 patients who received transplants facilitated by the National Marrow Donor Program between August 1991 and June 1999. Among patients surviving at least 28 days, 4% had primary graft failure (failure to achieve an absolute neutrophil count > 5 x 108/L before death or second stem-cell infusion). Multivariate logistic regression analysis showed that engraftment was associated with marrow matched at HLA-A, HLA-B, and DRB1; higher cell dose; younger recipient; male recipient; and recipient from a non -African American ethnic group. More rapid myeloid engraftment was associated with marrow serologically matched at H L A-A and HLA-B, DRB1 match, higher cell dose (in non-T-cell-depleted cases), younger recipient, recipient seronegativity for cytomegalovirus (CMV), male donor, no methotrexate for graft-versus-host disease prophylaxis, and transplantation done in more recent years. A platelet count higher than 50 x 109/L was achieved by 47% of patients by day 100. Conditional on survival to day 100, survival at 3 years was 61% in those with platelet engraftment at day 30, 58% in those with engraftment between day 30 and day 100, and 33% in those without engraftment at day 100 (P <.0001). Factors favoring platelet engraftment were higher cell dose, DRB1 allele match, recipient seronegativity for CMV, HLA-A and H L A-B serologically matched donor, and male donor. Secondary graft failure occurred in 10% of patients achieving initial engraftment, and 18% of those patients are alive. These data demonstrate that quality of engraftment is an important predictor of survival after URD bone marrow transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0034672165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034672165&partnerID=8YFLogxK

M3 - Article

C2 - 11110679

AN - SCOPUS:0034672165

VL - 96

SP - 4096

EP - 4102

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -